Abstract
Children diagnosed with cancer are commonly treated with anthracyclines, which have increased the number of survivors to more than 325,000 in the United States. However, anthracyclines are limited by their cardiotoxicity, which increases the risk of treatment-related complications. Survivors are more likely than their healthy siblings to experience heart failure, coronary artery disease, and stroke within the first 30 years after diagnosis. The mechanisms of anthracycline cardiotoxicity are not well understood. Cardiotoxicity can develop any time, from the start of chemotherapy to decades after its completion, and can manifest sub-clinically (e.g., echocardiographic abnormalities) or clinically (e.g., heart failure). However, not all survivors are affected equally, despite receiving similar doses of anthracyclines. Factors such as age at diagnosis, female sex, and cumulative anthracycline dose are risk factors for cardiotoxicity. Possible genetic risk factors that may explain the variability among survivors need to be explored. Identifying the highest-risk patients may help inform the frequency of monitoring during and after treatment and identify those who would benefit most from other treatment and prevention options, such as limiting the cumulative dose of anthracyclines, replacing them with liposomal anthracyclines, and using dexrazoxane as a cardioprotectant. The ultimate goal is to maximize the oncologic efficacy of anthracyclines and to minimize their late cardiotoxic effects in the vulnerable and less-studied population of childhood cancer survivors.
Keywords: Anthracycline, cardiotoxicity, childhood cancer survivors, late effects, radiation
Current Cancer Therapy Reviews
Title:Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Volume: 8 Issue: 2
Author(s): Melissa B. Diamond, Vivian I. Franco, Tracie L. Miller and Steven E. Lipshultz
Affiliation:
Keywords: Anthracycline, cardiotoxicity, childhood cancer survivors, late effects, radiation
Abstract: Children diagnosed with cancer are commonly treated with anthracyclines, which have increased the number of survivors to more than 325,000 in the United States. However, anthracyclines are limited by their cardiotoxicity, which increases the risk of treatment-related complications. Survivors are more likely than their healthy siblings to experience heart failure, coronary artery disease, and stroke within the first 30 years after diagnosis. The mechanisms of anthracycline cardiotoxicity are not well understood. Cardiotoxicity can develop any time, from the start of chemotherapy to decades after its completion, and can manifest sub-clinically (e.g., echocardiographic abnormalities) or clinically (e.g., heart failure). However, not all survivors are affected equally, despite receiving similar doses of anthracyclines. Factors such as age at diagnosis, female sex, and cumulative anthracycline dose are risk factors for cardiotoxicity. Possible genetic risk factors that may explain the variability among survivors need to be explored. Identifying the highest-risk patients may help inform the frequency of monitoring during and after treatment and identify those who would benefit most from other treatment and prevention options, such as limiting the cumulative dose of anthracyclines, replacing them with liposomal anthracyclines, and using dexrazoxane as a cardioprotectant. The ultimate goal is to maximize the oncologic efficacy of anthracyclines and to minimize their late cardiotoxic effects in the vulnerable and less-studied population of childhood cancer survivors.
Export Options
About this article
Cite this article as:
B. Diamond Melissa, I. Franco Vivian, L. Miller Tracie and E. Lipshultz Steven, Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer, Current Cancer Therapy Reviews 2012; 8 (2) . https://dx.doi.org/10.2174/157339412800675342
DOI https://dx.doi.org/10.2174/157339412800675342 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets Editorial (Thematic Issue: Current Management of Fetal and Neonatal Tumors)
Current Pediatric Reviews High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Is Type 2 Diabetes Mellitus a Predisposal Cause for Developing Hepatocellular Carcinoma?
Current Diabetes Reviews Ferulic Acid Activity in Topical Formulations: Technological and Scientific Prospecting
Current Pharmaceutical Design Signal Transduction of Steroidogenic Hormones to the Adrenal and Gonadal Mitochondria and the Possibilities for Combating Lipoid Congenital Adrenal Hyperplasia
Current Signal Transduction Therapy The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews Genetics and Genomics Interventions for Promoting Millets as Functional Foods
Current Genomics Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Effect of an Obesogenic Diet During the Juvenile Period on Growth Pattern, Fatness and Metabolic, Cardiovascular and Reproductive Features of Swine with Obesity/Leptin Resistance
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Markers: The Potential of “Omics” Approach
Current Molecular Medicine Gene Therapy for Chronic Granulomatous Disease: Current Status and Future Perspectives
Current Gene Therapy Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Incorporation of Selenocysteine into Proteins Using Peptide Ligation
Protein & Peptide Letters Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry